Publications

Found 1052 results
Filters: First Letter Of Last Name is W  [Clear All Filters]
2022
Ketcham, J. M., Haling, J., Khare, S., Bowcut, V., Briere, D. M., Burns, A. C., Gunn, R. J., Ivetac, A., Kuehler, J., Kulyk, S., Laguer, J., J Lawson, D., Moya, K., Nguyen, N., Rahbaek, L., Saechao, B., Smith, C. R., Sudhakar, N., Thomas, N. C., Vegar, L., Vanderpool, D., Wang, X., Yan, L., Olson, P., Christensen, J. G., and Marx, M. A. (2022) Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction. J Med Chem. 65, 9678-9690
Cao, L., Coventry, B., Goreshnik, I., Huang, B., Park, J. Sung, Jude, K. M., Marković, I., Kadam, R. U., Verschueren, K. H. G., Verstraete, K., Walsh, S. Thomas Rus, Bennett, N., Phal, A., Yang, A., Kozodoy, L., DeWitt, M., Picton, L., Miller, L., Strauch, E. - M., DeBouver, N. D., Pires, A., Bera, A. K., Halabiya, S., Hammerson, B., Yang, W., Bernard, S., Stewart, L., Wilson, I. A., Ruohola-Baker, H., Schlessinger, J., Lee, S., Savvides, S. N., K Garcia, C., and Baker, D. (2022) Design of protein binding proteins from target structure alone. Nature. 10.1038/s41586-022-04654-9
Cao, L., Coventry, B., Goreshnik, I., Huang, B., Park, J. Sung, Jude, K. M., Marković, I., Kadam, R. U., Verschueren, K. H. G., Verstraete, K., Walsh, S. Thomas Rus, Bennett, N., Phal, A., Yang, A., Kozodoy, L., DeWitt, M., Picton, L., Miller, L., Strauch, E. - M., DeBouver, N. D., Pires, A., Bera, A. K., Halabiya, S., Hammerson, B., Yang, W., Bernard, S., Stewart, L., Wilson, I. A., Ruohola-Baker, H., Schlessinger, J., Lee, S., Savvides, S. N., K Garcia, C., and Baker, D. (2022) Design of protein binding proteins from target structure alone. Nature. 10.1038/s41586-022-04654-9
Stille, J. K., Tjutrins, J., Wang, G., Venegas, F. A., Hennecker, C., Rueda, A. M., Sharon, I., Blaine, N., Miron, C. E., Pinus, S., Labarre, A., Plescia, J., Patrascu, M. Burai, Zhang, X., Wahba, A. S., Vlaho, D., Huot, M. J., T Schmeing, M., Mittermaier, A. K., and Moitessier, N. (2022) Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CL covalent inhibitors.. Eur J Med Chem. 229, 114046
Stille, J. K., Tjutrins, J., Wang, G., Venegas, F. A., Hennecker, C., Rueda, A. M., Sharon, I., Blaine, N., Miron, C. E., Pinus, S., Labarre, A., Plescia, J., Patrascu, M. Burai, Zhang, X., Wahba, A. S., Vlaho, D., Huot, M. J., T Schmeing, M., Mittermaier, A. K., and Moitessier, N. (2022) Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CL covalent inhibitors.. Eur J Med Chem. 229, 114046
Hanan, E. J., Braun, M. - G., Heald, R. A., MacLeod, C., Chan, C., Clausen, S., Edgar, K. A., Eigenbrot, C., Elliott, R., Endres, N., Friedman, L. S., Gogol, E., Gu, X. - H., Thibodeau, R. Hong, Jackson, P. S., Kiefer, J. R., Knight, J. D., Nannini, M., Narukulla, R., Pace, A., Pang, J., Purkey, H. E., Salphati, L., Sampath, D., Schmidt, S., Sideris, S., Song, K., Sujatha-Bhaskar, S., Ultsch, M., Wallweber, H., Xin, J., Yeap, S. K., Young, A., Zhong, Y., and Staben, S. T. (2022) Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα.. J Med Chem. 10.1021/acs.jmedchem.2c01422
Rohaim, A., Vermeulen, B. J. A., Li, J., Kümmerer, F., Napoli, F., Blachowicz, L., Medeiros-Silva, J., Roux, B., and Weingarth, M. (2022) A distinct mechanism of C-type inactivation in the Kv-like KcsA mutant E71V. Nat Commun. 13, 1574
Fu, J. Y., Muroski, J. M., Arbing, M. A., Salguero, J. A., Wofford, N. Q., McInerney, M. J., Gunsalus, R. P., Loo, J. A., and Loo, R. R. Ogorzale (2022) Dynamic acylome reveals metabolite driven modifications in . Front Microbiol. 13, 1018220
Xiong, X., Tian, S., Yang, P., Lebreton, F., Bao, H., Sheng, K., Yin, L., Chen, P., Zhang, J., Qi, W., Ruan, J., Wu, H., Chen, H., Breault, D. T., Wu, H., Earl, A. M., Gilmore, M. S., Abraham, J., and Dong, M. (2022) Emerging enterococcus pore-forming toxins with MHC/HLA-I as receptors. Cell. 185, 1157-1171.e22
Xiong, X., Tian, S., Yang, P., Lebreton, F., Bao, H., Sheng, K., Yin, L., Chen, P., Zhang, J., Qi, W., Ruan, J., Wu, H., Chen, H., Breault, D. T., Wu, H., Earl, A. M., Gilmore, M. S., Abraham, J., and Dong, M. (2022) Emerging enterococcus pore-forming toxins with MHC/HLA-I as receptors. Cell. 185, 1157-1171.e22
Chen, W. - H., Kim, J. H., Bu, W., Board, N. L., Tsybovsky, Y., Wang, Y., Hostal, A., Andrews, S. F., Gillespie, R. A., Choe, M., Stephens, T., Yang, E. Sung, Pegu, A., Peterson, C. E., Fisher, B. E., Mascola, J. R., Pittaluga, S., McDermott, A. B., Kanekiyo, M., M Joyce, G., and Cohen, J. I. (2022) Epstein-Barr virus gH/gL has multiple sites of vulnerability for virus neutralization and fusion inhibition. Immunity. 55, 2135-2148.e6
Wang, F., Li, L., Dou, Y., Shi, R., Duan, X., Liu, H., Zhang, J., Liu, D. D., Wu, J., He, Y., Lan, J., Lu, B., Feng, H., and Yan, J. (2022) Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants. Emerg Microbes Infect. 11, 548-551
Wang, F., Li, L., Dou, Y., Shi, R., Duan, X., Liu, H., Zhang, J., Liu, D. D., Wu, J., He, Y., Lan, J., Lu, B., Feng, H., and Yan, J. (2022) Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants. Emerg Microbes Infect. 11, 548-551
Said, M. Y., Kang, C. S., Wang, S., Sheffler, W., Salveson, P. J., Bera, A. K., Kang, A., Nguyen, H., Ballard, R., Li, X., Bai, H., Stewart, L., Levine, P., and Baker, D. (2022) Exploration of Structured Symmetric Cyclic Peptides as Ligands for Metal-Organic Frameworks. Chem Mater. 34, 9736-9744
Smith, C. R., Kulyk, S., Ahmad, M. Ud Din, Arkhipova, V., Christensen, J. G., Gunn, R. J., Ivetac, A., Ketcham, J. M., Kuehler, J., J Lawson, D., Thomas, N. C., Wang, X., and Marx, M. A. (2022) Fragment optimization and elaboration strategies - the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hits. RSC Med Chem. 13, 1549-1564
Smith, C. R., Aranda, R., Bobinski, T. P., Briere, D. M., Burns, A. C., Christensen, J. G., Clarine, J., Engstrom, L. D., Gunn, R. J., Ivetac, A., Jean-Baptiste, R., Ketcham, J. M., Kobayashi, M., Kuehler, J., Kulyk, S., J Lawson, D., Moya, K., Olson, P., Rahbaek, L., Thomas, N. C., Wang, X., Waters, L. M., and Marx, M. A. (2022) Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of -Deleted Cancers.. J Med Chem. 10.1021/acs.jmedchem.1c01900
Smith, C. R., Aranda, R., Bobinski, T. P., Briere, D. M., Burns, A. C., Christensen, J. G., Clarine, J., Engstrom, L. D., Gunn, R. J., Ivetac, A., Jean-Baptiste, R., Ketcham, J. M., Kobayashi, M., Kuehler, J., Kulyk, S., J Lawson, D., Moya, K., Olson, P., Rahbaek, L., Thomas, N. C., Wang, X., Waters, L. M., and Marx, M. A. (2022) Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of -Deleted Cancers.. J Med Chem. 10.1021/acs.jmedchem.1c01900
Liu, L., Wilcox, X. E., Fisher, A. J., Boyd, S. D., Zhi, J., Winkler, D. D., and Bulla, L. A. (2022) Functional and Structural Analysis of the Toxin-Binding Site of the Cadherin G-Protein-Coupled Receptor, BT-R, for Cry1A Toxins of . Biochemistry. 61, 752-766
Liu, L., Wilcox, X. E., Fisher, A. J., Boyd, S. D., Zhi, J., Winkler, D. D., and Bulla, L. A. (2022) Functional and Structural Analysis of the Toxin-Binding Site of the Cadherin G-Protein-Coupled Receptor, BT-R, for Cry1A Toxins of . Biochemistry. 61, 752-766
Moghadasi, S. Arad, Esler, M. A., Otsuka, Y., Becker, J. T., Moraes, S. N., Anderson, C. B., Chamakuri, S., Belica, C., Wick, C., Harki, D. A., Young, D. W., Scampavia, L., Spicer, T. P., Shi, K., Aihara, H., Brown, W. L., and Harris, R. S. (2022) Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 M/3CL in Living Cells. mBio. 10.1128/mbio.00784-22
Wicky, B. I. M., Milles, L. F., Courbet, A., Ragotte, R. J., Dauparas, J., Kinfu, E., Tipps, S., Kibler, R. D., Baek, M., DiMaio, F., Li, X., Carter, L., Kang, A., Nguyen, H., Bera, A. K., and Baker, D. (2022) Hallucinating symmetric protein assemblies. Science. 378, 56-61
Cong, A. T. Q., Witter, T. L., and Schellenberg, M. J. (2022) High-efficiency recombinant protein purification using mCherry and YFP nanobody affinity matrices. Protein Sci. 31, e4383
Chandran, S. S., Ma, J., Klatt, M. G., Dündar, F., Bandlamudi, C., Razavi, P., Wen, H. Y., Weigelt, B., Zumbo, P., Fu, S. Ning, Banks, L. B., Yi, F., Vercher, E., Etxeberria, I., Bestman, W. D., Paula, A. Da Cruz, Aricescu, I. S., Drilon, A., Betel, D., Scheinberg, D. A., Baker, B. M., and Klebanoff, C. A. (2022) Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. Nat Med. 28, 946-957
Chandran, S. S., Ma, J., Klatt, M. G., Dündar, F., Bandlamudi, C., Razavi, P., Wen, H. Y., Weigelt, B., Zumbo, P., Fu, S. Ning, Banks, L. B., Yi, F., Vercher, E., Etxeberria, I., Bestman, W. D., Paula, A. Da Cruz, Aricescu, I. S., Drilon, A., Betel, D., Scheinberg, D. A., Baker, B. M., and Klebanoff, C. A. (2022) Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. Nat Med. 28, 946-957
Wang, J., Sachpatzidis, A., Christian, T. D., Lomakin, I. B., Garen, A., and Konigsberg, W. H. (2022) Insight into the Tumor Suppression Mechanism from the Structure of Human Polypyrimidine Splicing Factor (PSF/SFPQ) Complexed with a 30mer RNA from Murine Virus-like 30S Transcript-1. Biochemistry. 61, 1723-1734

Pages